Abstract
Diseases of the liver encompass a wide variety of clinical conditions that range from mild abnormalities on liver testing to end-stage liver disease with intrahepatic and extrahepatic manifestations and complications. These also range from acute, self-limited presentations to fulminant disease with rapid liver failure to chronic, low-level disease and also to chronic liver disease that progresses slowly over time. While the history and physical signs of this broad range of clinical disorders are quite similar, often with nonspecific findings with broad-range differentials, laboratory evaluation is critical to sorting through these disease processes. It is critical for family physicians to have an understanding of liver pathology and the laboratory assessment of the hepatic system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286. CrossRef PubMed
Kojaoglanian T. Hepatitis A. Pediatr Rev. 2010;31(8):348–50. CrossRef PubMed
Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012;86(11):1027–34. PubMed
Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223–30. PubMed
CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1–37.
CDC. Updated recommendations from the ACIP for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR. 2009;58:1–36.
Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for the use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep. 2019;68:153–6.
Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the Advisory Committee on Immunization Practices for the use of hepatitis a vaccines for Postexposure prophylaxis and for Preexposure prophylaxis for international travel. MMWR Morb Moral Wkly Rep. 2018;67:1216–20.
Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39:S26–30. CrossRef PubMed
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–41. CrossRef PubMed
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;2012(9):CD002799.
Terrault NA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.
Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67(RR-1):1–31.
Gitnick G. Non-A, non-B hepatitis: etiology and clinical course. Annu Rev Med. 1984;35:265–78. CrossRef PubMed
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83. CrossRef PubMed PubMedCentral
Seef LB. Natural history of hepatitis C. Hepatology. 1997;26(Suppl 1):21S–8. CrossRef
Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodes J, Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639. CrossRef PubMed
Mitruka K, Thornton K, Cusick S, Centers for Disease Control and Prevention, et al. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based model – Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):393–8.
Tran TT. Hepatitis C: who should treat hepatitis C virus? The role of the primary care provider. Clin Liver Dis. 2018;11(3):66–8.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.
Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58–67. CrossRef PubMed
AASLD/ISDA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 20 Mar 2020.
USPSTF. Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement. JAMA. 2020;323(10):970–5.
National Institutes of Health. Management of hepatitis C: 2002. National Institutes of Health consensus conference statement. 10–12 June 2002. http://consensus.nih/gov/2002/2002HepatitisC2002116PDF.pdf. Accessed 20 Mar 2020.
Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998;101(3 Pt1):481–5.
Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut. 1997;41:845–50. CrossRef PubMed PubMedCentral
Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009;30(1):3–13. CrossRef PubMed
Dugum MF, McCullough AJ. Acute alcoholic hepatitis, the clinical aspects. Clin Liver Dis. 2016;20(3):499–508.
Yamini D, Lee SH, Avanesyan A, Walter M, Runyon B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol. 2014;49:453–6.
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–33.
Moyer VA, Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(3):210–8. PubMed
Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38(Suppl 2):S44–8. CrossRef PubMed
Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24:483–90. CrossRef PubMed
Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41. CrossRef PubMed
Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–8.
Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209. CrossRef PubMed
Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C coinfection. Clin Infect Dis. 2005;40:588–93. CrossRef PubMed
Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13. CrossRef PubMed
Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464–73. CrossRef PubMed PubMedCentral
Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9. CrossRef PubMed
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence – SEER 9 Regs research data, Nov 2009 Sub (1973–2007). Bethesda: National Cancer Institute; 2010 April.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. CrossRef PubMed PubMedCentral
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27. CrossRef PubMed
Lok AS, Sterling RK, Everhart JE, HALT-C Trial Group, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502. CrossRef PubMed
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36. CrossRef PubMed
Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74. CrossRef PubMed
El Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63. CrossRef PubMed
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
O’Gurek, D.T. (2022). Diseases of the Liver. In: Paulman, P.M., Taylor, R.B., Paulman, A.A., Nasir, L.S. (eds) Family Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-54441-6_97
Download citation
DOI: https://doi.org/10.1007/978-3-030-54441-6_97
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-54440-9
Online ISBN: 978-3-030-54441-6
eBook Packages: MedicineReference Module Medicine